First Trust Advisors LP grew its holdings in AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) by 106.8% during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 70,869 shares of the specialty pharmaceutical company’s stock after purchasing an additional 36,607 shares during the quarter. First Trust Advisors LP owned approximately 0.21% of AMAG Pharmaceuticals worth $1,382,000 at the end of the most recent quarter.
Other hedge funds have also added to or reduced their stakes in the company. Piedmont Investment Advisors LLC acquired a new stake in shares of AMAG Pharmaceuticals in the second quarter valued at approximately $156,000. Meeder Asset Management Inc. grew its position in shares of AMAG Pharmaceuticals by 590.9% in the second quarter. Meeder Asset Management Inc. now owns 8,947 shares of the specialty pharmaceutical company’s stock valued at $174,000 after purchasing an additional 7,652 shares during the last quarter. Hartford Investment Management Co. acquired a new stake in shares of AMAG Pharmaceuticals in the second quarter valued at approximately $325,000. PNC Financial Services Group Inc. grew its position in shares of AMAG Pharmaceuticals by 94.9% in the first quarter. PNC Financial Services Group Inc. now owns 25,652 shares of the specialty pharmaceutical company’s stock valued at $518,000 after purchasing an additional 12,491 shares during the last quarter. Finally, Sei Investments Co. grew its position in shares of AMAG Pharmaceuticals by 83.0% in the first quarter. Sei Investments Co. now owns 28,209 shares of the specialty pharmaceutical company’s stock valued at $568,000 after purchasing an additional 12,793 shares during the last quarter.
Shares of AMAG opened at $22.45 on Friday. The company has a current ratio of 2.06, a quick ratio of 1.95 and a debt-to-equity ratio of 0.99. The company has a market cap of $801.49 million, a P/E ratio of -3.93 and a beta of 0.48. AMAG Pharmaceuticals, Inc. has a 1 year low of $11.93 and a 1 year high of $26.10.
Several brokerages recently issued reports on AMAG. ValuEngine raised shares of AMAG Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Wednesday, June 6th. BidaskClub raised shares of AMAG Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Tuesday, August 14th. Leerink Swann began coverage on shares of AMAG Pharmaceuticals in a research note on Monday, May 21st. They set a “market perform” rating and a $24.65 price objective on the stock. B. Riley raised shares of AMAG Pharmaceuticals from a “neutral” rating to a “buy” rating and upped their price objective for the company from $23.00 to $30.00 in a research note on Friday, June 15th. Finally, Janney Montgomery Scott downgraded shares of AMAG Pharmaceuticals from a “buy” rating to a “neutral” rating and set a $20.00 price objective on the stock. in a research note on Friday, June 15th. One analyst has rated the stock with a sell rating, seven have assigned a hold rating and three have assigned a buy rating to the company. The company presently has a consensus rating of “Hold” and a consensus target price of $22.85.
In other AMAG Pharmaceuticals news, CEO William K. Heiden sold 5,000 shares of the stock in a transaction that occurred on Tuesday, August 7th. The shares were sold at an average price of $25.00, for a total transaction of $125,000.00. Following the transaction, the chief executive officer now owns 328,015 shares of the company’s stock, valued at $8,200,375. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Company insiders own 4.00% of the company’s stock.
AMAG Pharmaceuticals Company Profile
AMAG Pharmaceuticals, Inc, a biopharmaceutical company, manufactures, develops, and commercializes therapeutics for maternal and women's health, anemia management, and cancer supportive care in the United States. It markets Makena, a hydroxyprogesterone caproate injection to reduce the risk of preterm birth in women pregnant with a single baby who have a history of singleton spontaneous preterm birth; Feraheme (ferumoxytol), an intravenous iron replacement therapeutic agent for the treatment of iron deficiency anemia in adult patients who have intolerance to oral iron or have had unsatisfactory response to oral iron, as well as patients who have chronic kidney disease; Intrarosa(prasterone) vaginal insert steroid for the treatment of dyspareunia due to menopause; and MuGard Mucoadhesive Oral Wound Rinse for the management of oral mucocitis/stomatiits and various types of oral wounds.
Recommended Story: Dow Jones Industrial Average (DJIA)
Receive News & Ratings for AMAG Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AMAG Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.